1. Home
  2. RVPH vs HSPO Comparison

RVPH vs HSPO Comparison

Compare RVPH & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • HSPO
  • Stock Information
  • Founded
  • RVPH 2006
  • HSPO 2014
  • Country
  • RVPH United States
  • HSPO United States
  • Employees
  • RVPH N/A
  • HSPO N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • HSPO Blank Checks
  • Sector
  • RVPH Health Care
  • HSPO Finance
  • Exchange
  • RVPH Nasdaq
  • HSPO Nasdaq
  • Market Cap
  • RVPH 88.0M
  • HSPO 91.5M
  • IPO Year
  • RVPH N/A
  • HSPO 2022
  • Fundamental
  • Price
  • RVPH $2.09
  • HSPO $11.78
  • Analyst Decision
  • RVPH Strong Buy
  • HSPO
  • Analyst Count
  • RVPH 5
  • HSPO 0
  • Target Price
  • RVPH $11.40
  • HSPO N/A
  • AVG Volume (30 Days)
  • RVPH 1.8M
  • HSPO 3.4K
  • Earning Date
  • RVPH 11-14-2024
  • HSPO 01-01-0001
  • Dividend Yield
  • RVPH N/A
  • HSPO N/A
  • EPS Growth
  • RVPH N/A
  • HSPO 2.63
  • EPS
  • RVPH N/A
  • HSPO 0.28
  • Revenue
  • RVPH N/A
  • HSPO N/A
  • Revenue This Year
  • RVPH N/A
  • HSPO N/A
  • Revenue Next Year
  • RVPH N/A
  • HSPO N/A
  • P/E Ratio
  • RVPH N/A
  • HSPO $41.67
  • Revenue Growth
  • RVPH N/A
  • HSPO N/A
  • 52 Week Low
  • RVPH $0.60
  • HSPO $10.80
  • 52 Week High
  • RVPH $4.83
  • HSPO $12.41
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 60.41
  • HSPO 55.44
  • Support Level
  • RVPH $1.78
  • HSPO $11.68
  • Resistance Level
  • RVPH $2.15
  • HSPO $12.10
  • Average True Range (ATR)
  • RVPH 0.15
  • HSPO 0.14
  • MACD
  • RVPH 0.02
  • HSPO -0.00
  • Stochastic Oscillator
  • RVPH 88.30
  • HSPO 32.32

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

Share on Social Networks: